Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Nobel Prize Winners Help Us Find a $125 Stock That Could be Worth $500-Plus

Page 1 of 2

Eugene Fama was a name many investors never heard before the University of Chicago professor won this year’s Nobel Prize in Economics. Yet Dr. Fama has had a tremendous impact on the investment community over the past 50 years.

Fama’s research has shown that value stocks outperform growth stocks in the long run. He has demonstrated that small-cap stocks offer greater returns than large-cap stocks over time, and that the market leaders of the recent past are likely to continue leading the market in the future.

Articles explaining these concepts are found in academic journals and include math that could challenge the understanding of many college graduates. Yet, these ideas are easily applied by individual investors. Like many great thinkers, Fama has made difficult ideas simple to understand.

Value investing can be applied with a number of tools. Price-to-earnings (P/E), price-to-book (P/B) and price-to-sales (P/S) ratios are popular, and all work well if applied with discipline.

Small-cap stocks can be rewarding in the long run. While there are a number of opportunities among small caps, most traders will find there are just as many opportunities among large-cap stocks.

Market leaders are defined with relative strength (RS), a tool we apply frequently when looking for stocks to trade. Fama’s work in this area has also been confirmed by real-world trading experience.

Fama shared this year’s award with Dr. Robert Shiller, who popularized the cyclically adjusted P/E ratio, among his many accomplishments, and Dr. Lars Peter Hansen, who developed a complex model that is used to test theories of how markets set prices.

Several other Nobel Prizes have gone to researchers who provide valuable information to investors. The 2002 prize, for example, went to Daniel Kahneman for his work in behavioral finance, which provides an intellectual framework for applying technical analysis to the markets. In 1997, Robert Merton and Myron Scholes were recognized by the Nobel Committee for their work with the late Fischer Black to develop an options pricing model. In 1990, Harry Markowitz, Merton Miller and William Sharpe were honored for the development of modern portfolio theory.

We have read a number of papers written by these economists, along with the work of other economists. While their ideas might seem abstract, they are directly applicable to investing. We have built entire trading systems around the ideas in those papers.

Siemens AG (ADR) (NYSE:SI)

A trade that the Nobel Prize-winning ideas point to right now is in Siemens AG (ADR) (NYSE:SI). This company produces items ranging from home appliances to subway train cars.

When a business is diverse, it often trades at a discount in the market because analysts are unsure how to value the different operating divisions. SI is trading at an unusually steep discount to its potential value and has a PEG ratio of only 0.22. The PEG ratio compares the P/E ratio to the earnings growth rate. A stock is considered to be trading at fair value when the PEG ratio is 1.

The PEG ratio can also be used to develop price targets. With SI expected to earn $9.16 per share next year, and with the company expected to grow earnings at 61.8% a year going forward, if the P/E were equal to the earnings growth rate, SI would be worth more than $500 a share, but it is currently trading under $125.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!